April 8, 2010 –
CureDM, LLC announced that an agreement has been signed with
Sanofi-Aventis (EURONEXT: SAN and NYSE: SNY) for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
“We are extremely pleased to have the opportunity to partner with one of the most innovative global pharmaceutical companies,”...
[PDF] CureDM's Press Release -
[PDF] Sanofi-Aventis' Press Release -
April 8, 2010 – CureDM, LLC announced that an agreement has been signed with Sanofi-Aventis (EURONEXT: SAN and NYSE: SNY) for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
“We are extremely pleased to have the opportunity to partner with one of the most innovative global pharmaceutical companies,”... [PDF] CureDM's Press Release - [PDF] Sanofi-Aventis' Press Release -
